Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Agilent Technologies Inc(A)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for A
10/08/2026: A (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Agilent Technologies is a prominent player in the life sciences and diagnostics sector, offering a broad range of analytical instruments and laboratory services. The company benefits from a resilient business model characterized by high-margin recurring revenue and a strong presence in pharmaceutical research. Its primary growth story revolves around advancements in personalized medicine and laboratory automation. However, the company faces risks from fluctuating biopharma R&D budgets and intense competition from major industry peers. The stock may suit investors seeking a stable, long-term exposure to scientific research, though it is important to monitor global research spending and margin performance as key indicators of health.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Agilent offers steady growth but typically lacks the explosive top-line acceleration associated with high-growth tech. |
| Momentum investor | Mixed fit | Momentum is conditional on positive sector sentiment and sustained R&D spending upturns. |
| Value investor | Mixed fit | The stock often trades at a premium multiple, requiring attractive entry points for value-focused investors. |
| Dividend investor | Strong fit | The company has a reliable history of modest but consistent dividend growth and payout stability. |
| Low-risk investor | Strong fit | Low beta relative to broader markets and a strong recurring revenue base provide relative stability. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock is susceptible to broader market sentiment regarding pharmaceutical capital expenditure. |
| Valuation risk | Medium | High P/E multiples during growth phases can lead to corrections if earnings miss expectations. |
| Competition risk (Thermo Fisher) | Medium / high | Agilent faces intense pressure from Thermo Fisher's massive scale and integrated product ecosystem. |
| Business quality | Strong | Agilent possesses high margins, sticky customer relationships, and recurring revenue models. |
| Dividend income | Low | Dividend yields are generally modest, catering more to growth than high-yield income seekers. |
| Execution risk | Medium | Successfully integrating acquisitions is crucial to maintaining product differentiation. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 11.69% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 47.68B USD | Price to earnings Ratio 33.35 | 1Y Target Price 176.5 |
Price to earnings Ratio 33.35 | 1Y Target Price 176.5 | ||
Volume (30-day avg) 2.5M shares | Beta 1.21 | 52 Weeks Range 107.98 - 176.79 | Updated Date 10/07/2026 |
52 Weeks Range 107.98 - 176.79 | Updated Date 10/07/2026 | ||
Dividends yield (FY) 0.60% | Basic EPS (TTM) 5.07 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Sciences and Applied | Chromatography and Mass Spectrometry instruments, reagents, and software. | The primary engine generating recurring sales through high-demand lab equipment. |
| CrossLab Services | Maintenance, repairs, and consulting for laboratory equipment. | Provides stable, recurring revenue regardless of new equipment sales cycles. |
| Diagnostics and Genomics | Clinical diagnostic tests and molecular biology tools. | High-growth niche tied to oncology and personalized medicine trends. |
| Geography (Global) | Exposure to North America, Europe, China, and rest of world. | Geographic diversification helps hedge against regional economic slowdowns. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 33.35 | Forward PE 23.87 | Enterprise Value 48.80B | Price to Sales(TTM) 6.47 |
Enterprise Value 48.80B | Price to Sales(TTM) 6.47 | ||
Enterprise Value to Revenue 6.62 | Enterprise Value to EBITDA 23.98 | Shares Outstanding 281.97M | Shares Floating 280.96M |
Shares Outstanding 281.97M | Shares Floating 280.96M | ||
Percent Insiders 0.19 | Percent Institutions 95.42 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.